You found a weight loss method that works for you: the pounds are coming off, your clothes are fitting better and you're ...

A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Sleep-apnoea-tackling Resmed is dreaming big but the question is: what can upset the Aussie biotech's growth story?

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...